Tevogen Inc. TVGN
Tevogen Inc. (Nasdaq: TVGN) is an infectious disease drug developer. Its lead program, TVGN 489 (ExacTcell allogeneic, off-the-shelf CTL therapy), is in Phase 1 for COVID-19 in high-risk and immunocompromised patients; Long COVID.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| TVGN 489 | COVID-19 (high-risk ambulatory adults); Long COVID | cell therapy | Phase 1 |
| Other ExacTcell T-cell candidates | Oncology and other infectious disease targets | cell therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 infectious disease companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.